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We previously identified a gene signature predicted to regulate the epithelial-mesenchymal transition (EMT) in both epithelial
tissue stem cells and breast cancer cells. A phenotypic RNA interference (RNAi) screen identified the genes within this 140-gene
signature that promoted the conversion of mesenchymal epithelial cell adhesion molecule-negative (EpCAM) breast cancer
cells to an epithelial EpCAM/high phenotype. The screen identified 10 of the 140 genes whose individual knockdown was suffi-
cient to promote EpCAM and E-cadherin expression. Among these 10 genes, RNAi silencing of the SWI/SNF chromatin-remod-
eling factor Smarcd3/Baf60c in EpCAM breast cancer cells gave the most robust transition from the mesenchymal to epithelial
phenotype. Conversely, expression of Smarcd3/Baf60c in immortalized human mammary epithelial cells induced an EMT. The
mesenchymal-like phenotype promoted by Smarcd3/Baf60c expression resulted in gene expression changes in human mammary
epithelial cells similar to that of claudin-low triple-negative breast cancer cells. These mammary epithelial cells expressing
Smarcd3/Baf60c had upregulated Wnt5a expression. Inhibition of Wnt5a by either RNAi knockdown or blocking antibody re-
versed Smarcd3/Baf60c-induced EMT. Thus, Smarcd3/Baf60c epigenetically regulates EMT by activating WNT signaling
pathways.
The epithelial-mesenchymal transition (EMT) is a reversibledevelopmental process, whereby epithelial cells lose cell-cell
adhesion and apical-basolateral polarity, while acquiring a mes-
enchymal front-back polarity and increased cellular invasiveness
(1). During metastatic tumor progression, this developmental
program becomes reactivated to confer tumor cells with enhanced
migratory and invasive properties (2, 3). The opposing process of
mesenchymal-epithelial transition (MET) reestablishes the epi-
thelial state, as demonstrated by formation of epithelial tissues and
organs in development and by metastatic colonization of epithe-
lial tumors to distant organs (4). Understanding the molecular
mechanisms controlling EMT, and the reverse process of MET, is
important for development of new therapeutic strategies for the
prevention and treatment of metastatic cancer and many other
diseases such as organ fibrosis and impaired wound healing (5).
Cells undergoing EMT maintain the same genomic back-
ground in both mesenchymal and epithelial states, but during the
progression of EMT, the gene expression profile significantly
changes. The onset of EMT involves the repression of epithelium-
specific genes and activation of mesenchyme-specific genes (6).
Changes in promoter-specific DNA methylation altered expres-
sion of microRNAs (miRNAs) and enhanced expression of the
transcription factors Snail, Slug, and Twist contribute to the in-
duction of EMT (7, 8). We recently defined a signaling network
involving mitogen-activated protein kinase kinase kinase 4
(MAP3K4) and Jun N-terminal protein kinase (JNK) whose inhi-
bition reprograms epithelial tissue stem cells to undergo an EMT
(9). MAP3K4/JNK-mediated phosphorylation of the histone
acetyltransferase CBP stimulated acetylation of specific lysine
marks in histones H2A/H2B that served to maintain an epithelial
phenotype. Loss of MAP3K4/JNK activation of CBP promoted
EMT in these tissue stem cells. This study was the first to demon-
strate how loss of histone H2A/H2B acetylation could induce cells
to lose the epithelial phenotype and enter EMT (9). Gene expres-
sion analysis of epithelial stem cells entering EMT and the claudin-
low subtype of triple-negative breast cancer discovered a statisti-
cally significant intersecting EMT gene signature (9). Claudin-low
triple-negative breast cancers characteristically have EMT fea-
tures, are resistant to therapy, and demonstrate a propensity to
metastasize to the lung and brain parenchyma (10–13).
On the basis of the gene signature derived from the overlapping
epithelial stem cell and claudin-low breast cancer expression pro-
files, we hypothesized that the 140 genes upregulated in the EMT
signature functioned to promote the mesenchymal phenotype.
Using SUM149 and SUM229 breast cancer cells that exist in cul-
ture as dual populations of epithelial cell adhesion molecule-neg-
ative (EpCAM) (mesenchymal-like) and EpCAM/high (epithe-
lial-like) cells, we designed a phenotypic RNA interference (RNAi)
screen to identify individual genes whose targeted knockdown in
EpCAM cells promoted the EpCAM/high epithelial phenotype
(13–15). Using this RNAi strategy, the SWI/SNF chromatin-re-
modeling factor Smarcd3/Baf60c was identified as a novel regula-
tor of EMT. While small interfering RNA (siRNA)-mediated
knockdown of Smarcd3/Baf60c induced a MET in EpCAM
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SUM149 and SUM229 cells, expression of Smarcd3/Baf60c in
human mammary epithelial cells (HMECs) promoted EMT.
Smarcd3/Baf60c activated the EMT program in HMECs by epige-
netic induction of Wnt5a signaling. These results define Smarcd3/
Baf60c as important for maintenance of the EMT properties and
mesenchymal phenotype of claudin-low EpCAM SUM149 and
SUM229 breast cancer cells.
MATERIALS AND METHODS
Cell lines, culture conditions, constructs, and transfections. The pri-
mary HMEC line, immortalized using the retrovirus pBabe-hygro-
hTERT (hygro stands for hygromycin, and hTERT stands for human tel-
omerase reverse transcriptase), was cultured as previously described (16).
SUM149 and SUM229 breast cancer cells were cultured in HuMEC me-
dium (Life Technologies; catalog no. 12752-010) containing 5% fetal bo-
vine serum (FBS), 1% penicillin and streptomycin (PS) plus bovine pitu-
itary extract and HuMEC supplement or Ham’s F-12 medium containing
5% FBS, 1% PS plus 5 g/ml insulin and 1 g/ml hydrocortisone, respec-
tively. 293T cells were cultured in Dulbecco’s modified Eagle’s high-glu-
cose medium with 10% FBS and 1% PS. Transfection of 293T cells was
performed in 15-cm dishes for 24 h with Lipofectamine Plus (Invitrogen)
according to the manufacturer’s specifications. The Smarcd3/Snail/Slug
Gateway entry plasmid was subcloned into a lentiviral FLAG-Gateway
destination vector. The lentiviral FLAG-Gateway destination vector was a
kind gift from Ben Major.
Lentivirus production and infections of HMECs. To produce repli-
cation-incompetent lentivirus, 293T cells were cotransfected with either
pGIPZ empty vector, FLAG-Smarcd3/Snail/Slug lentiviral Gateway con-
structs in combination with pMD2.G and psPAX2 (Addgene) using Lipo-
fectamine Plus reagent (Invitrogen). Twenty-four hours later, the cell
medium was changed. Viral supernatants were harvested at 48 h post-
transfection by ultracentrifugation, and viral pellets were resuspended in
300 l base medium. HMECs were infected overnight with 100 l lenti-
virus in 6 g/ml Polybrene. Puromycin (3 g/ml) was used to select trans-
duced cells. Selection was complete 7 days after infection. Expression of
Smarcd3/Snail/Slug was measured by quantitative reverse transcription-
PCR (qRT-PCR).
Fluorescence-activated cell sorting (FACS). Cells were trypsinized
and filtered into single-cell suspensions, resuspended in Hanks’ balanced
salt solution containing 2% FBS (HF medium), and incubated with anti-
bodies for 30 min at 4°C. Cells were stained with the following antibodies,
antibodies directed against EpCAM-FITC (EpCAM conjugated to fluo-
rescein isothiocyanate [FITC]) (catalog no. 10109; Stem Cell Technolo-
gies), EpCAM-APC (EpCAM conjugated to allophycocyanin [APC])
(catalog no. 347200; BD), Cd49f-PE-Cy5 (Cd49f conjugated to phyco-
erythrin [PE] and Cy5) (catalog no. 551129; BD), Cd44-APC (catalog no.
559942; BD), or Cd24-FITC (catalog no. 555427; BD). Unbound antibod-
ies were washed from cells using HF medium. For analytical flow, cells
were fixed with 3% paraformaldehyde and analyzed using a Beckman-
Coulter CyAn instrument. For sterile live-cell flow cytometry, cells were
sorted using a Sony iCyt/reflection instrument.
RNAi screening conditions, immunofluorescence, and high-con-
tent imaging. For the RNAi screen, EpCAM SUM149 or SUM229 cells
were reverse transfected in fibronectin-coated 96-well plates (Greiner)
with 25 nM siRNA smart pools (Dharmacon) containing the combination
of 4 different siRNA oligonucleotides for each target or control gene
(siRNA targeting ubiquitin B [siUBB] for siRNA knockdown efficiency;
siRNA targeting glyceraldehyde-3-phosphate dehydrogenase [siGAPDH]
for a negative control; siRNA targeting Snail and Slug [siSnail/Slug] for a
positive control). Target genes were plated in duplicate on three replicate
plates, and control genes were plated 2 times for UBB, 6 times for
GAPDH, and 8 times for Snail/Slug on three replicate plates. After 6 days
in culture, cells were fixed with 3% paraformaldehyde, permeabilized with
0.1% Triton X, and stained with nuclear 4=,6=-diamidino-2-phenylindole
(DAPI) stain, EpCAM (catalog no. 01420; Stem Cell Technologies) and
E-cadherin (catalog no. 3195S; Cell Signaling) antibodies. EpCAM (con-
jugated to secondary Alexa Fluor 555) and E-cadherin (conjugated to
secondary Alexa Fluor 488) fluorescence was measured using the high-
content BD Pathway 855 microscope system. Changes in EpCAM and
E-cadherin expression were quantitatively measured on a single-cell basis
as a function of the percent change in cellular fluorescence using the
CellProfiler image analysis software. Results were the compilation of two
independent screens performed in triplicate.
Confocal imaging. ZO-1 (catalog no. 33 -9100; Invitrogen) immuno-
fluorescence experiments were conducted with an Olympus FluoView
1000 laser scanning confocal microscope with 40 UPLFLN 1.3-numer-
ical-aperture (NA) oil objective with lasers at 405 and 488 nm. Single
z-plane images of Alexa Fluor 488 and DAPI channels (1 or 2.4 zoom)
were acquired sequentially with identical laser transmissivity and photo-
multiplier tube (PMT) voltage settings, and 4-frame Kalman averaging.
Western blotting of whole-cell and nuclear lysates. Whole-cell and
nuclear lysates were isolated as previously described (17). Western blots
were performed with the following antibodies: antibodies to EpCAM (cat-
alog no. 71916; Abcam), E-cadherin (catalog no. 610181; BD), fibronectin
(catalog no. CP70; Calbiochem), N-cadherin (catalog no. 76057; Abcam),
vimentin (catalog no. 5741S; Cell Signaling), -tubulin (catalog no.
T6557; Sigma), FLAG (catalog no. M5 F4042/F7425; Sigma), Snail (cata-
log no. 3895S; Cell Signaling), Slug (catalog no. 9585S; Cell Signaling),
Brg1 (catalog no. sc-17796X; Santa Cruz), Brm (catalog no. 15597; Ab-
cam), phosphorylated protein kinase C (phospho-PKC) (catalog no.
9371S; Cell Signaling), phospho-JNK (catalog no. 9251S; Cell Signaling),
-catenin (catalog no. C7207; Sigma), and Smarcd3/Baf60c. Smarcd3/
Baf60c antibody was a kind gift from Lorenzo Puri.
ChIP assays. Chromatin immunoprecipitation (ChIP) assays were
performed as previously described (9). ChIP assays were quantified by
real-time PCR using ABsolute blue SYBR green PCR mix (Thermo Scien-
tific) and the Applied Biosystems Fast 7500 real-time PCR system. Fold
enrichment was determined by the 2CT method. PCR primers were
designed to amplify approximately 75- to 100-bp fragments from
genomic DNA using Primer Express 3.0 (Applied Biosystems). ChIP–
qRT-PCR primers include the following: Cdh1 sense (5=-ACCCCCTCTC
AGTGGCGT-3=) and antisense (5=-GGAGCGGGCTGGAGTCTG);
Cd44 sense (5=-AGTGGATGGACAGGAGGATG-3=) and antisense (5=-T
TATGTCCTTCTGGGCTCT); Cldn4 sense (5=-TCAGCCTTCCAGGTC
CTCAA-3=) and antisense (5=-CCCCATGGAGGCCATTG-3=); Wnt5a
sense (5=-CCTATTTTGCTCCCCGTT-3=) and antisense (5=-AAGAGTC
AGCCCCAAATT-3=).
Invasion assays. Cells were plated on growth factor-reduced Matrigel
(BD Biosciences)-coated 8-m-pore Transwell chambers. After 24 h, in-
vasion assays were terminated. Noninvading cells were removed from the
top of the Transwells by washing and swabbing. Invasive cells were quan-
tified by fixing chambers in 3% paraformaldehyde for 10 min and staining
with nuclear DAPI stain. For each Transwell, five 10 fields were imaged
and counted.
Real-time qRT-PCR. qRT-PCR was performed as previously de-
scribed (9).
Agilent gene expression microarrays. Transfected and control
HMEC lines were profiled as described previously using 44,000 (44K)
human oligonucleotide microarrays (Agilent Technologies, Santa Clara,
CA, USA) (13, 18). The probes or genes for all analyses were filtered by
requiring the lowest normalized intensity values in both sample and con-
trol to be 10. The normalized log2 ratios (Cy5 sample/Cy3 control) of
probes mapping to the same gene (Entrez identification [ID] as defined by
the manufacturer) were averaged to generate independent expression es-
timates. At least three biological replicates were used for each transfected
gene (i.e., each Cy5 sample). For Cy3 controls, we used the empty vector
cell line, which was the same for all samples. All microarray data are
available in the University of North Carolina (UNC) Microarray Database
(https://genome.unc.edu/).
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Gene signatures. The previously published claudin-low predictor and
the differentiation score were evaluated as previously described (13). For
each infected HMEC line (i.e., Smarcd3, Slug and Snail), we derived a gene
signature by performing a one-class significance analysis of microarrays
(SAM) with a false discovery rate of 0%. The resulting gene lists can be
found in Table S4 in the supplemental material. An enrichment score for
each individual signature (up- and downregulated genes combined) was
evaluated in the previously published UNC337 data set (GSE18229) of
breast cancer samples representing all the intrinsic molecular subtypes. To
do so, we calculated the inner product of each signature (gene ratio) and
the gene expression value of each breast tumor sample. Subtype calls in the
UNC337 data set were used as provided in Gene Expression Omnibus
(GEO) (13).
Statistical analysis. Gene overlap between two signatures was esti-
mated using exact hypergeometric probabilities implemented in R pack-
age (http://cran.r-project.org). All microarray cluster analyses were dis-
played using Java Treeview version 1.1.4r2. Average-linkage hierarchical
clustering was performed using Cluster v3.0 (19).
Microarray data accession number. All microarray data have been
deposited in the GEO database under accession number GSE40145.
RESULTS
SUM149 and SUM229 breast cancer cells maintain epithelial
and mesenchymal populations. SUM149 and SUM229 cells
maintain two distinct populations of EpCAM and EpCAM/high
cells with similar growth rates (Fig. 1A and B) that exhibit the
profiles of claudin-low and basal-like breast cancer cells, respec-
tively, by gene expression analysis (13). Gupta and colleagues
modeled the behavior of the dual population in SUM149 cells as
being in a phenotypic equilibrium with each other (14). Further char-
acterization of the two populations revealed the mesenchymal ver-
sus epithelial characteristics of EpCAM and EpCAM/high cells,
respectively. EpCAM cells demonstrated a spindle-like mesen-
chymal morphology contrasting with the rounded epithelial mor-
phology of the EpCAM/high cells (Fig. 1C). Both EpCAM/high
cell lines express modest levels of E-cadherin with SUM149 cells
having more expression of E-cadherin than SUM229 cells. Immu-
nofluorescence and Western blotting confirmed the absence or
low expression of the epithelial markers EpCAM and E-cadherin
in EpCAM SUM149 and SUM229 cells (Fig. 1C to E). Compared
to EpCAM/high cells, EpCAM cells showed elevated protein ex-
pression of the mesenchymal markers fibronectin, N-cadherin,
and vimentin (Fig. 1D and E) and had filamentous actin stress
fibers consistent with a front-back end polarized mesenchymal
phenotype (not shown). The mesenchymal phenotype was even
more pronounced in the EpCAM SUM229 cells than in the
EpCAM/high SUM229 cells. Changes in protein expression in
EpCAM cells versus EpCAM/high cells were mirrored with de-
creased mRNA expression of the epithelial markers E-cadherin and
EpCAM (Fig. 1F and G). There was also increased expression of the
mesenchymal markers N-cadherin, vimentin, transforming growth
factor  (TGF-), and the EMT-inducing transcription factors Snail,
Slug, and Twist in EpCAM cells than in EpCAM/high cells
(Fig. 1F to I). Functionally, the EpCAM SUM149 and SUM229
cells were 3- and 8-fold more invasive through growth factor-
reduced Matrigel than the EpCAM/high cells, respectively (Fig.
1J). These results demonstrated that the epithelial EpCAM/high
and mesenchymal EpCAM populations of SUM149 and
SUM229 cells are morphologically and functionally distinct.
RNAi screen identifies genes important for EMT. EpCAM
SUM149 and SUM229 cells were used in RNAi screens to identify
genes important for maintenance of the mesenchymal phenotype
(Fig. 2A). Fluorescence-activated cell sorting (FACS) purity
checks before each screen showed less than 0.5% contamination of
the EpCAM population of cells with EpCAM/high cells when the
screens were initiated (Fig. 2B), indicating that increases in
EpCAM and E-cadherin expression resulted from a cellular tran-
sition from the mesenchymal EpCAM to epithelial
EpCAM/high state. Validation of our screen image analysis was
achieved by titrating set percentages of EpCAM/high SUM149
cells into an EpCAM background. The percent cellular fluores-
cence of EpCAM and E-cadherin immunostaining assessed by
high-content image analysis closely recapitulated the titrated per-
centages (not shown). This robust RNAi screening platform was
used for identification of genes whose knockdown induced a mes-
enchymal to epithelial transition (MET) in EpCAM SUM149
and SUM229 cells.
Pools of four independent siRNA oligonucleotides were used
to individually target the 140 upregulated genes within the EMT
gene signature shared by epithelial stem cells developmentally en-
tering EMT and claudin-low breast cancer (see Table S1 in sup-
plemental material) (9). With the exception of Slug, Twist, vimen-
tin, and N-cadherin, these genes are uncharacterized with respect
to EMT.
As proof of principle for the RNAi screening strategy, we si-
lenced known EMT-inducing genes Snail and Slug and measured
the increase in epithelial markers EpCAM and E-cadherin by im-
munofluorescence (Fig. 2C and D). These experiments demon-
strated that siRNA-mediated knockdown of Snail or Slug in the
mesenchymal EpCAM SUM149 cells resulted in increased
EpCAM and E-cadherin expression, loss of the mesenchymal phe-
notype, and gain of the epithelial phenotype within 6 days post-
transfection (Fig. 2C to E). At 6 days posttransfection, control
GAPDH siRNA-treated EpCAM cells had a background of less
than 3% EpCAM- or E-cadherin-positive cells (Fig. 2C and D). In
contrast, dual knockdown of Snail and Slug resulted in 26 and
10% EpCAM or E-cadherin-positive SUM149 cells, respectively
(Fig. 2D). A highly reproducible 3- to 5-fold change in EpCAM
and E-cadherin percent fluorescence was observed with siRNA-
mediated knockdown of Slug or Snail versus control GAPDH
knockdown (Fig. 2D).
The RNAi screen targeted 140 upregulated genes within the
EMT gene signature and identified 10 genes whose individual
knockdown resulted in the morphological transition between
EpCAM and EpCAM/high phenotypes in both SUM149 and
SUM229 cells (Fig. 2F; see Table S2 in supplemental material).
Compared to control GAPDH siRNA knockdown, siRNA-medi-
ated knockdown of these 10 EMT regulatory genes demonstrated
a statistically significant increase in the percent EpCAM and
E-cadherin cellular fluorescence (Fig. 3A and B). The 10 identified
EMT regulatory genes included the following: Slug, Cdh2,
Smarcd3/Baf60c, ABR, Rnf130, EphA4, Met, Ptprb, Fhl1, and
RRAGD (Fig. 3A to D; see Table S3 in supplemental material for
gene functions). In addition to upregulation of EpCAM and
E-cadherin protein expression, siRNA-mediated knockdown of
these EMT regulatory genes induced morphological changes char-
acteristic of an epithelial, cobblestone morphology.
Of the 10 EMT regulatory genes identified in the phenotypic
RNAi screen, five genes, including Cdh2, Smarcd3/Baf60c, Fhl1,
Rnf130, and RRAGD were upregulated in the mesenchymal
EpCAM cells relative to the epithelial EpCAM/high SUM149
and SUM229 cells (Fig. 4A). Deconvolution of siRNA oligonucle-
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FIG 1 SUM149 and SUM229 breast cancer cells maintain epithelial and mesenchymal populations. (A and B) FACS analysis of SUM149 and SUM229 cells
showing EpCAM and EpCAM/high populations. (C) Epithelial and mesenchymal properties of EpCAM/high and EpCAM populations shown by phase
microscopy and immunostaining with nuclear DAPI (blue) stain and anti-E-cadherin (green) and anti-EpCAM (red) antibodies. Arrowheads indicate the
EpCAM cells in the parental SUM229 and SUM149 cell lines. Bars, 100 m. (D and E) Reduced EpCAM and E-cadherin protein expression with elevated
fibronectin, N-cadherin, and vimentin protein in EpCAM cells. The presence and level of various proteins in the parental (P), EpCAM/high (), and EpCAM
() SUM149 (E) and SUM229 (F) breast cancer cells are shown. The data in panels A to E are representative of the data from at least two independent
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otide pools for each of the 10 genes showed efficient knockdown of
the EMT regulatory target genes by at least two of the four oligo-
nucleotides, consistent with increases in EpCAM and E-cadherin
expression being the result of on-target knockdown (Fig. 4B).
Functionally, knockdown of ABR, Cdh2, Smarcd3/Baf60c, or Slug
expression resulted in significant decreases in cellular invasiveness
through growth factor-reduced Matrigel (Fig. 4C; see Table S3 in
supplemental material). RNAi knockdown of several of the EMT
regulatory genes induced a decrease in mRNA expression of the
EMT-inducing transcription factors Snail and Slug (Fig. 4D and E;
see Table S3). Thus, the RNAi screen effectively identified genes
whose selective loss was sufficient to promote the epithelial phe-
notype of SUM149 and SUM229 breast cancer cells.
Smarcd3/Baf60c is an epigenetic regulator of EMT. Of the
EMT regulatory genes identified in the screen, RNAi silencing of
the SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c in
EpCAM breast cancer cells gave the most robust transition from
the mesenchymal to epithelial phenotype. Smarcd3/Baf60c has
the potential to affect a broad network of genes through its epige-
netic regulatory function as a member of the SWI/SNF chroma-
tin-remodeling complex (20–23). The specificity of the Smarcd3/
Baf60c knockdown was demonstrated by rescue of the EpCAM
phenotype by transfection of a siRNA resistant to knockdown
(Fig. 5A and B), indicating that the increases in EpCAM and E-
cadherin expression resulted from targeted Smarcd3/Baf60c
knockdown and not an off-target response to the siRNA.
To determine its role in the regulation of EMT, FLAG-tagged
Smarcd3/Baf60c was stably expressed in human mammary epithelial
cells (HMECs) at levels comparable to mesenchymal EpCAM
SUM149 cells (Fig. 5C). HMECs expressing Smarcd3/Baf60c (D3-
HMECs) demonstrated phenotypic changes indicative of EMT
(Fig. 5D). D3-HMECs lost their epithelial cell morphology and be-
came mesenchymal cell-like, with diminished expression of epithelial
cell-cell adhesion markers EpCAM and E-cadherin and gain of ex-
pression of the mesenchymal marker vimentin (Fig. 5D). Western
blotting confirmed the decreased expression of EpCAM and E-
cadherin with gain of fibronectin and vimentin (Fig. 5E). Of the
EMT-inducing transcription factors, Lef1 and Zeb2 mRNAs were
increased compared to empty vector control HMECs (EV-
HMECs) (Fig. 5F). Furthermore, the epithelial cell-cell adhesion
genes E-cadherin, EpCAM, Krt7, Krt19, Cldn4, and Cldn7 were
downregulated (Fig. 5F). Notably, mRNA expression of the tight
junction genes Cldn4 and Cldn7 was reduced 90% compared to
EV-HMECs. EV-HMECs and D3-HMECs when analyzed by
FACS, profiled as separate cellular populations based on antigenic
expression levels of epithelial differentiation markers EpCAM/
Cd49f and breast cancer stem cell markers Cd44/Cd24. Compared
to EV-HMECs, the D3-HMECs demonstrated a reduction in
the epithelial integrin Cd49f and gain in the prometastatic gly-
coprotein Cd44 with no change in the prodifferentiation gly-
coprotein Cd24 (Fig. 5G). D3-HMECs also showed increased
cytoplasmic staining of the tight junctions protein zona occludins
(ZO-1) compared to EV-HMECs (Fig. 5H). The changes in ZO-1
staining were accompanied with a loss of epithelial cobblestone
morphology and tight junctions (Fig. 5H). These results support
the role of Smarcd3/Baf60c as an EMT-inducing chromatin-re-
modeling factor that promotes loss of the epithelial phenotype by
a reduction in cell-cell adhesions with gain of the mesenchymal
phenotype.
Smarcd3/Baf60c expression in HMECs induces a claudin-
low gene signature. We performed gene arrays to measure expres-
sion changes in D3-HMECS relative to EV-HMECs. Additionally,
we compared gene expression changes of D3-HMECS with Snail-
and Slug-expressing HMECs (Snail-HMECs and Slug-HMECs,
respectively) to define gene networks important for EMT. Hierar-
chical cluster analysis of gene array data from D3-, Slug-, and
Snail-HMECs with respect to the 9-cell line claudin-low predictor
described by Prat et al. (13) revealed that the gene expression
profiles of D3-HMECs clustered similarly to the claudin-low sig-
nature of human breast cancer (Fig. 6A and B; see Table S4 in
supplemental material). Conversely, the gene expression profiles
of Slug- and Snail-HMECs demonstrated substantially less over-
lap with the claudin-low signature (Fig. 6A and B; see Table S4).
Of the D3-, Slug-, and Snail-HMECs, D3-HMECs had the most
significant gene intersection (P value 	 0.0001) with the claudin-
low signature sharing 7% upregulated and 13% downregulated
genes (Fig. 6B; see Table S4). D3- and Slug-HMECs shared a sig-
nificant gene intersection (P value 	 0.0001) with 41% upregu-
lated and 18% downregulated shared genes (Fig. 6C; see Table S4),
suggesting that Smarcd3/Baf60c and Slug affect an overlapping
EMT gene network. To further emphasize the significance of the
D3-HMEC/claudin-low association, the gene expression profile
of D3-HMECs was compared to the five intrinsic molecular sub-
types of human breast tumors catalogued in the UNC337 data set.
Tumors from the claudin-low subtype showed highest expression
of the D3-HMEC signature in comparison with basal-like, HER2-
enriched, luminal A and luminal B tumors (Fig. 6D). The differ-
entiation predictor described by Prat et al. (13), which uses gene
expression profiles to determine the cellular relatedness to the
normal breast epithelial differentiation hierarchy from mammary
stem cells (MaSCs) to mature luminal cells showed that D3-
HMECs had the lowest differentiation score compared to Slug-
and Snail-HMECs (Fig. 6E) (24). This suggests that D3-HMECs
profile more similarly to MaSCs and more importantly to a less-
differentiated mesenchymal, claudin-low phenotype than Slug-
and Snail-HMECs. Collectively, these findings demonstrate that
Smarcd3/Baf60c induces an EMT gene expression program in
HMECs similar to that of the claudin-low breast cancer subtype.
Molecular characterization of the Smarcd3/Baf60c-induced
EMT in HMECs showed a more profound phenotypic conversion
than that of the Snail- or Slug-induced EMT in HMECs. Morpho-
logical changes included a loss of cell-cell adhesions in D3-
HMECs, whereas Snail- and Slug-HMECs maintained a partial
degree of epithelial cell-cell adhesions through either E-cadherin
experiments. (F and G) Reduced EpCAM and E-cadherin mRNA expression and elevated N-cadherin, vimentin, and TGF expression in EpCAM cells than in
EpCAM/high cells. (H and I) Elevated mRNA expression of EMT-inducing transcription factors Snail, Slug, and Twist in EpCAM cells compared to EpCAM/high
cells measured by qRT-PCR. The values in panels F to I are means plus standard errors of the means (SEMs) (error bars) of three independent experiments
performed in triplicate. (J) Increased invasiveness of mesenchymal EpCAM compared to epithelial EpCAM/high cells through growth factor-reduced Matrigel-
coated Transwell chambers. Statistical significance was evaluated by an unpaired Student’s t test and indicated as follows: , P value 	 0.001; , P value 	 0.01.
Values are means plus SEMs of two independent experiments performed in triplicate.
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FIG 2 RNAi screening strategy for EMT regulatory genes. (A) Schematic depicting the RNAi screening strategy. (B) Separation of EpCAM/high and EpCAM
SUM149 cells by FACS shows less than 0.5% EpCAM/high contamination in the EpCAM cells. Data depict FACS analysis of three individual cell sorts used for
the primary RNAi screen. Q2, quadrant 2. (C) Acquisition of the epithelial phenotype by mesenchymal EpCAM cells following siRNA-mediated knockdown
of Snail, Slug, or both Snail/Slug genes as shown by immunostaining with nuclear DAPI (blue) stain, anti-E-cadherin (green), and anti-EpCAM (red) antibodies.
Bar, 500 m. (D) Elevated EpCAM and E-cadherin percent cellular fluorescence quantitated on a single-cell basis following siRNA-mediated knockdown of the
genes indicated. Values are means plus SEMs (error bars) of 8 independent wells. (E) Elevated mRNA expression of epithelial markers EpCAM and E-cadherin
following siRNA-mediated knockdown of Snail and Slug measured by qRT-PCR. Values are means plus SEMs of three independent experiments performed in
triplicate. (F) Representative plate image from the RNAi screen shows expression of epithelial markers E-cadherin (green) and EpCAM (red) by immunofluo-
rescence in EpCAM SUM149 cells following siRNA-mediated knockdown of target genes in duplicate wells shown in columns 2 to 11 in rows A to H; siGAPDH
in columns 1 and 12, rows B to D and E to H, respectively; siSnail/Slug in columns 1 and 12, rows E to H and A to D, respectively; and siUBB in wells A1 and H12.
Positive hits are indicated by white numerals as follows: 1, Fhl1; 2, EphA4; 3, Rnf130. Data are representative of duplicate RNAi screens for 140 genes performed
in triplicate.
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or EpCAM expression (Fig. 7A). Immunofluorescence, Western
blotting, and qRT-PCR analysis of D3- and Slug-HMECs showed
decreased E-cadherin and increased vimentin, N-cadherin, and
fibronectin expression (Fig. 7A to C), while Snail-HMECs had
preferentially decreased EpCAM expression (Fig. 7A and B). Both
Snail- and Slug-HMECs had a 2- to 4-fold increase in Smarcd3/
Baf60c mRNA expression (Fig. 7C). Snail- and Slug-HMECs also
had increased mRNA levels for the EMT-inducing transcription
factor Zeb2 similar to Smarcd3/Baf60c (Fig. 5F and 7D). Like D3-
HMECs, Slug-HMECs preferentially repressed the cell-cell adhe-
sion tight junction genes Cldn4 and Cldn7, possibly contributing
to the disruption of epithelial cell polarity (Fig. 7E). Cumulatively,
these findings suggest that Smarcd3/Baf60c and Slug impact an
overlapping EMT network.
SWI/SNF complex regulates WNT signaling through induc-
tion of Wnt5a expression. Wnt5a regulates cellular polarity and
cell-cell adhesion through activation of noncanonical WNT sig-
naling pathways (25–27). Expression of Wnt5a was upregulated in
FIG 3 RNAi screen identifies genes important for EMT. (A and B) Elevated EpCAM and E-cadherin percent cellular fluorescence quantitated on a single-cell
basis following siRNA-mediated knockdown of the genes indicated. Values are means plus SEMs of 6 independent wells from the primary screen. Statistical
significance was evaluated by an unpaired Student’s t test and indicated as follows: , P value 	 0.001; , P value 	 0.01. (C and D) Acquisition of the epithelial
phenotype by mesenchymal EpCAM cells following siRNA-mediated knockdown of the genes indicated is shown by immunostaining of SUM149 (C) and
SUM229 (D) EpCAM cells with nuclear DAPI (blue) stain, anti-E-cadherin (green), and anti-EpCAM (red) antibodies. Bars, 100 m.
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two independent D3-HMEC lines (Fig. 8A; see Table S4 in sup-
plemental material). Activation of Wnt5a-regulated signaling
pathways in D3-HMECs was demonstrated by increased PKC
phosphorylation and expression of TGF (Fig. 8A and B). Nuclear
localization of -catenin was decreased in the D3-HMECs, sug-
gesting decreased -catenin function associated with Smarcd3/
Baf60c expression (Fig. 8B).
The ATP-dependent catalytic components of multisubunit
SWI/SNF chromatin-remodeling complexes are either Brm or
Brg1 (20). In D3-HMECs, Brg1 expression was increased and co-
immunoprecipitated with FLAG-Smarcd3/Baf60c (Fig. 8C and
D). Chromatin immunoprecipitation (ChIP) assays were used to
determine whether the Brg1/Smarcd3/Baf60c complex resided on
the Wnt5a gene promoter (Fig. 8E). Brg1 regulates transcription
of E-cadherin and Cd44 (28), so we used these genes as controls
for ChIP assays. Smarcd3/Baf60c and Brg1 bound to the promot-
ers of E-cadherin, Cd44, and Wnt5a genes but not to the promoter
of the Cldn4 gene (Fig. 8E and F). Parallel ChIP assays for the
histone methylation mark H3K4me3, which correlates with active
transcription, showed loss of this histone mark on the promoters
FIG 4 EMT regulatory genes affect cellular invasiveness and expression of EMT-inducing transcription factors. (A) Expression levels of EMT regulatory genes
in EpCAM/high cells compared to EpCAM cells measured by qRT-PCR. N-cad, N-cadherin. (B) Deconvolution of siRNA smart pools demonstrates knock-
down of EMT regulatory genes with at least two individual siRNA oligonucleotides per gene in SUM149 EpCAM cells as shown by qRT-PCR. (C) Cellular
invasiveness through Matrigel-coated Transwell chambers of SUM149 EpCAM cells following siRNA-mediated knockdown of the indicated EMT regulatory
genes. Statistical significance was evaluated by an unpaired Student’s t test and indicated as follows: , P value 	 0.01; , P value 	 0.05. Values are means plus
SEMs of two independent experiments performed in triplicate. (D and E) Expression changes of EMT-inducing transcription factors in EpCAM SUM149 cells
following siRNA-mediated knockdown of the indicated EMT regulatory genes measured by qRT-PCR. The values in panels A, B, D, and E are means plus SEMs
of at least three independent experiments performed in triplicate.
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FIG 5 Smarcd3/Baf60c is an epigenetic regulator of EMT. (A) Western blot comparing levels of expression of Smarcd3/Baf60c in EpCAM SUM149 cells before
() and after siRNA-mediated knockdown of Smarcd3 (siD3) and following the rescue of Smarcd3 expression. (B) Mesenchymal EpCAM cells do not acquire
the epithelial phenotype following the rescue of Smarcd3 expression as shown by immunostaining with nuclear DAPI (blue) stain, anti-E-cadherin (green) and
anti-EpCAM (red) antibodies. Representative images of two independent experiments performed in quadruplicate are shown. Bar, 100 m. (C) Expression of
Smarcd3/Baf60c in HMECs at levels comparable to those in EpCAM SUM149 cells. EV, empty vector; D31 and D32, two independent HMEC clones expressing
Baf60c. (D) Smarcd3/Baf60c-expressing HMECs (D3-HMECs) gain a mesenchymal phenotype with loss of epithelial properties as shown by phase microscopy
and immunostaining of EV- and D3-HMECs with nuclear DAPI (blue) stain, anti-E-cadherin (green), anti-EpCAM (red), or antivimentin (green) antibodies.
Bars, 500 m. (E) Loss of epithelial markers EpCAM and E-cadherin and gain of mesenchymal markers fibronectin and vimentin in D3-HMECs shown by
Western blotting. (F) Elevated mRNA expression of EMT-inducing transcription factors Lef1 and Zeb2 and reduced expression of epithelial and cell adhesion
markers in D3-HMECs measured by qRT-PCR. Values are means plus SEMs of three independent experiments performed in triplicate. (G) Different antigenic
profiles in EV- versus D3-HMECs demonstrated by FACS analysis with epithelial differentiation markers anti-EpCAM (FITC) and anti-Cd49f (PE-Cy5) or
cancer stem-like markers anti-Cd44 (APC) and anti-Cd24 (FITC). (H) Loss of epithelial cell polarity in D3-HMECs shown by confocal microscopy of EV- and
D3-HMECs stained with nuclear DAPI (blue) stain and anti-ZO1 (green) antibody. Images are representative of at least two independent experiments.
Bars, 50 m.
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of repressed E-cadherin and Cldn4 genes and gain on the promot-
ers of induced Cd44 and Wnt5a genes (Fig. 7G). Cumulatively, the
findings indicate that Smarcd3/Baf60c and Brg1 bind the Wnt5a
promoter for the activation of Wnt5a transcription.
Inhibition of Wnt5a restores the epithelial phenotype. Simi-
lar elevation of Wnt5a expression was observed in Slug-HMECs
and EpCAM SUM149 and SUM229 cells, supporting a role for
Wnt5a in the induction of EMT in these cells with upregulated
Smarcd3/Baf60c expression (Fig. 9A and B). To determine
whether Wnt5a was responsible for inducing the loss of epithelial
characteristics resulting from Smarcd3/Baf60c expression, we in-
hibited Wnt5a expression using RNAi in D3-HMECs. siRNA-me-
diated knockdown of Wnt5a phenotypically converted mesenchy-
mal-like cells lacking cell-cell adhesions to epithelial colonies with
a cobblestone morphology (Fig. 9C). Wnt5a knockdown resulted
in the increased mRNA and protein expression of epithelial mark-
ers E-cadherin and EpCAM (Fig. 9D and E). Although expression
of epithelial tight junction genes Cldn4 and Cldn7 was reduced by
90% in D3-HMECs relative to EV-HMECs (Fig. 5F), knockdown
of Wnt5a in D3-HMECs resulted in a 10-fold increase in Cldn4
and Cldn7 (Fig. 9D). The EMT-inducing transcription factor Lef1
and the mesenchymal marker vimentin, which were each induced
FIG 6 Smarcd3/Baf60c expression induces a claudin-low gene signature. (A) Gene expression profiles of D3-HMECs cluster with the claudin-low gene signature.
Heat map compares gene expression of D3-HMECs, Slug-HMECs, and Snail-HMECs to the 9-cell line claudin-low predictor. Upregulated genes (red) and
downregulated genes (green) are indicated. (B and C) Venn diagrams depict shared genes between D3-, Slug-, and Snail-HMECs compared to the claudin-low
predictor or compared to each other. (D) Claudin-low human tumors show the highest expression of D3-HMEC genes among breast cancer subtypes, as
demonstrated by the mean expression of D3-, Slug-, and Snail-HMEC genes across the subtypes of breast cancer in the UNC337 data set. P values were calculated
by comparing gene expression means across all subtypes using an analysis of variance (ANOVA) test. Each plus symbol represents a distinct tumor sample within
the data set. (E) Differentiation scores compare D3-, Slug-, and Snail-HMECs relative to EV-HMECs showing the lowest differentiation propensity of D3-
HMECs. The P value was calculated by comparing gene expression means across all breast epithelial cell lineages.
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with Smarcd3/Baf60c expression (Fig. 5D and E), were repressed
with knockdown of Wnt5a (Fig. 9D). Knockdown of Wnt5a re-
pressed PKC phosphorylation, consistent with inhibition of the
WNT signaling pathway (Fig. 9E). Treatment of D3-HMECs with
a Wnt5a blocking antibody inhibited cellular invasiveness by 70%
compared to untreated D3-HMECs (Fig. 9F), demonstrating that
the phenotypic changes coincided with functional changes indic-
ative of a more epithelial cell state. Functionally, the blocking an-
FIG 7 Phenotypic comparison of Snail-, Slug-, and Smarcd3-induced EMT. (A) Loss of the epithelial phenotype with gain of mesenchymal properties in D3-,
Slug-, and/or Snail-HMECs as shown by phase microscopy and immunostaining with nuclear DAPI (blue) stain, anti-E-cadherin (green), and anti-EpCAM (red)
antibodies. (B) Western blotting shows reduced protein expression for epithelial markers EpCAM or E-cadherin and elevated protein expression of mesenchymal
markers fibronectin and vimentin in Snail-, Slug-, and D3-HMECs. (C) Elevated gene expression of mesenchymal markers N-cadherin, vimentin, and Smarcd3/Baf60c
in Snail-, Slug-, and D3-HMECs measured by qRT-PCR. (D and E) Elevated gene expression of EMT-inducing transcription factors and reduced expression of epithelial
cell-cell adhesion markers in Snail- and Slug-HMECs measured by qRT-PCR. Values are means plus SEMs of three independent experiments performed in triplicate. The
images in panel A and data in panels B and C are representative of the results of at least two independent experiments.
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tibody was as effective as siRNA-mediated knockdown of Wnt5a.
These results demonstrated that Smarcd3/Baf60c promoted EMT
in D3-HMECs by promoting Wnt5a expression.
DISCUSSION
We describe a directed phenotypic RNAi screen that identified
genes whose individual knockdown was sufficient to promote
MET in the EpCAM population of SUM149 and SUM229 breast
cancer cells. While it has long been accepted that EMT is a revers-
ible process during development, few studies have examined the
opposite process of MET (3, 5). Our RNAi screen targeted 140
genes from an EMT gene signature shared by epithelial stem cells
developmentally entering EMT and claudin-low breast cancer
cells with properties of EMT and stemness (9). Ten of the 140
genes were identified as EMT regulatory genes, whose individual
siRNA-mediated knockdown was sufficient to promote MET.
Three of the genes, Slug, Met receptor tyrosine kinase, and N-
cadherin, are well-defined regulators of EMT and provide valida-
tion of the screen (1). The other seven genes have no defined role
in EMT. The functions of the seven genes do suggest their poten-
tial importance in the phenotypic reprogramming associated with
EMT. For instance, EphA4 and Ptprb/VE-Ptp represent a receptor
tyrosine kinase and phosphatase, respectively, that in develop-
ment have been shown to be critical regulators of angiogenesis
(29–32). Fhl1 localizes to focal adhesions where it promotes cell
spreading in a TGF-dependent manner, and Rnf130 is a ring
finger protein with putative E3 ligase activity (33–37). Consistent
with its knockdown inhibiting invasion of mesenchymal
EpCAM SUM149 cells, ABR is a guanine nucleotide exchange
factor (GEF)/GTPase-activating protein (GAP) for Rho and
Cdc42 GTPases, and RRAGD is a poorly characterized GTPase
with homology to Ras (38–41). Among these genes, Rnf130 is an
interesting gene candidate for future studies with respect to EMT.
Our preliminary findings have demonstrated that combined
knockdown of Rnf130, Slug, and Smarcd3/Baf60c produced syn-
ergistic effects in promoting an epithelial morphology in fully
mesenchymal claudin-low SUM159 breast cancer cells. As a puta-
tive E3 ligase, there are no defined substrates for ubiquitination by
Rnf130. The findings are suggestive that these genes, in addition to
Slug, Met, N-cadherin, and Smarcd3/Baf60c, are likely members
of a signaling network controlling EMT.
We demonstrated that Smarcd3/Baf60c is a novel epigenetic
EMT regulatory gene. Smarcd3/Baf60c was the only gene identi-
fied in the RNAi screen whose knockdown strongly increased both
EpCAM and E-cadherin expression, decreased Snail and Slug ex-
pression, inhibited invasiveness, and was also upregulated in
EpCAM cells relative to EpCAM/high SUM149 and SUM229
breast cancer cells. Smarcd3/Baf60c as a member of the multisub-
unit ATP-dependent SWI/SNF chromatin-remodeling complex
has the ability to epigenetically modulate gene expression pro-
grams (20, 21). Smarcd3/Baf60c induced an EMT gene expression
program in HMECs, indicating that Smarcd3/Baf60c plays an im-
portant role in promoting the EMT properties and mesenchymal
phenotype of these cells. Consistent with their related roles as
transcriptional regulators, siRNA-mediated knockdown of Slug
induced a MET similar to inhibition of Smarcd3/Baf60c expres-
sion. Notably, ectopic expression of either Smarcd3/Baf60c or
Slug similarly induced the expression of Wnt5a, suggesting that
Smarcd3/Baf60c affects an EMT gene network that overlaps with
the EMT-inducing function of Slug. To our knowledge, this is the
first report of Smarcd3/Baf60c promoting an epigenetic repro-
gramming event responsible for inducing an EMT in HMECs.
Also, Smarcd3/Baf60c maintains the mesenchymal phenotype in
claudin-low EpCAM populations of SUM149 and SUM229 cells.
There is an expanding awareness that SWI/SNF chromatin-
remodeling complexes play critical functions in reprogramming
events relevant to EMT and lineage commitment. Brg1, one of the
FIG 8 SWI/SNF complex regulates noncanonical WNT signaling through
induction of Wnt5a expression. (A) Elevated expression of Wnt5a and TGF
in D3-HMECs shown by qRT-PCR. Values are means plus SEMs of three
independent experiments performed in triplicate. (B) Activation of nonca-
nonical WNT signaling with inhibition of canonical WNT signaling shown by
Western blotting for elevated phosphorylation of PKC and reduced nuclear
(nuc) but not whole-cell (wc) -catenin protein expression. (C) Induced Brg1
protein expression with the expression of Smarcd3/Baf60c in HMECs shown
by Western blotting with the antibodies indicated. (D) Brg1 coimmunopre-
cipitates with FLAG-Smarcd3/Baf60c in HMECs. IP, immunoprecipitation;

-FLAG, anti-FLAG antibody. The results shown in panels B to D are repre-
sentative of at least two independent experiments. (E to G) Elevated Smarcd3/
Baf60c, Brg1, and H3K4me3 on the promoters of the indicated genes in D3-
HMECs compared to EV-HMECs as measured by ChIP– qRT-PCR. Values are
means plus SEMs of three independent experiments performed in duplicate.
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catalytic components of SWI/SNF chromatin-remodeling com-
plex, is important in the reprogramming of somatic cells to in-
duced pluripotent stem (iPS) cells (42, 43). MET was shown re-
cently to occur simultaneously with the reprogramming of
fibroblasts to iPS cells, directly connecting MET to iPS cell gener-
ation (44). Our results indicate that studies are warranted to de-
termine whether Smarcd3/Baf60c expression is repressed in these
cells as a switch to induce MET during iPS cell reprogramming. In
the context of regulating EMT and MET, WNT signaling has been
shown to be an important collaborator with TGF for inducing
EMT. WNT signaling, for example, contributes to the metastatic
progression of pancreatic cancer and melanoma (45–47). In D3-
HMECs, we showed that both Smarcd3/Baf60c and Brg1 bind the
promoters of Wnt5a and E-cadherin. Wnt5a expression is in-
FIG 9 Inhibition of Wnt5a restores epithelial adherens junctions. (A) Wnt5a expression correlates with the mesenchymal phenotype of EpCAM cells. Elevated
gene expression of Wnt5a in Slug-HMECs is similar to D3-HMECs measured by qRT-PCR. (B) Elevated gene expression of Wnt5a in EpCAM SUM149 and
SUM229 cells compared to EpCAM/high SUM149 and SUM229 cells measured by qRT-PCR from two independent FACS sorts. Values in panels A and B are
means plus SEMs of two independent experiments performed in triplicate. (C) siRNA-mediated knockdown of Wnt5a partially restores the epithelial phenotype
of D3-HMECs as shown by phase microscopy. (D) siRNA-mediated knockdown of Wnt5a increases mRNA expression of epithelial and cell-cell adhesion
markers and decreases expression of the mesenchymal marker vimentin and the EMT-inducing transcription factor Lef1. Data are measured by qRT-PCR, and
values are means plus SEMs of three independent experiments performed in triplicate. (E) Western blotting showing increased protein expression of EpCAM and
E-cadherin with loss of PKC phosphorylation in D3-HMECs transfected with siWnt5a. (F) Reduced invasiveness through growth factor-reduced Matrigel-
coated Transwell chambers of D3-HMECs treated with siWnt5a or two different concentrations of the Wnt5a blocking antibody (
-Wnt5a) compared to
untreated D3-HMECs. Statistical significance was evaluated by an unpaired Student’s t test and indicated as follows: , P value 	 0.001; , P value 	 0.01.
Values are means plus SEMs of two independent experiments performed in triplicate.
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duced, stimulating WNT signaling, while E-cadherin expression is
repressed to promote EMT. Together, these findings show the
importance of Smarcd3/Baf60c in controlling the commitment to
the mesenchymal cellular phenotype. Further studies are war-
ranted to determine the function of SWI/SNF-regulated epige-
netic changes that contribute to the claudin-low subtype of breast
cancer.
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